olivLaw · US equity research
United-Guardian, Inc. UG
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844 · Vertical: Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
United-Guardian makes cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness ingredients through its Guardian Laboratories division. Net sales rose 12% in the first half of 2026, a recovery after the largest cosmetic distributor had worked off excess stock, though pharmaceutical pricing and trade policy remain sensitive points.
At the close of 04 Nov 2026, United-Guardian, Inc. (UG) stock was 6.86 USD (+0.44% on the day), with market capitalisation 31.5 m USD, P/E 14.9 on diluted EPS of 0.46 USD over the last 12 months, dividend yield 10.20%, beta 0.22, 52-week range 5.62–8.20 USD. Latest reported quarter (Q2 2026): revenue of 3.1 m USD (+9.5% YoY), net income of 728.6 k USD (+16.2% YoY), diluted EPS 0.16 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 48.0
- neutral
- Bollinger (20, 2)
- 6.54 – 7.17
- in the upper half of the band · %B 0.51 · band width 9.1%
- SMA 50 / 200
- 7.03 / 6.95
- mixed trend
- MACD (12, 26, 9)
- -0.04 / -0.07
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −2.0% | −1.1% | −0.9 pp | — |
| 3 months | −4.9% | −0.5% | −4.4 pp | — |
| 6 months | +2.2% | +4.4% | −2.2 pp | — |
| Year to date | +11.4% | +12.3% | −1.0 pp | — |
| 1 year | −3.0% | +13.5% | −16.5 pp | +4.5% |
| 3 years | +18.5% | +76.4% | −57.9 pp | −12.3% |
| 5 years | −50.6% | +63.7% | −114.3 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.1 m | 2.5 m | 2.5 m | 2.8 m | 2.3 m | 3.0 m | 2.9 m | 3.1 m |
| Cost of revenue | 1.4 m | 1.2 m | 1.1 m | 1.3 m | 1.3 m | 1.6 m | 1.4 m | 1.6 m |
| Research & development | 111.1 k | 131.1 k | 114.4 k | 107.9 k | 117.1 k | 124.3 k | 115.0 k | 124.4 k |
| Operating income | 949.1 k | 556.4 k | 610.9 k | 695.5 k | 215.1 k | 721.9 k | 642.4 k | 754.1 k |
| Depreciation & amortisation | 21.7 k ≈ | 26.3 k | 25.0 k | 25.2 k ≈ | 27.3 k ≈ | 30.7 k | 29.0 k | 29.4 k ≈ |
| Pre-tax income | 1.1 m | 640.8 k | 708.0 k | 790.6 k | 326.5 k | 818.0 k | 1.0 m | 917.6 k |
| Income tax | 230.8 k | 137.1 k | 147.1 k | 163.8 k | 58.0 k | 168.4 k | 214.2 k | 189.0 k |
| Net income | 865.5 k | 503.7 k | 560.9 k | 626.8 k | 268.4 k | 649.6 k | 818.9 k | 728.6 k |
| Diluted EPS | 0.19 | — | 0.12 | 0.14 | 0.06 | — | 0.18 | 0.16 |
| Operating cash flow | 1.2 m ≈ | 269.3 k | 322.1 k | 303.2 k ≈ | 1.0 m ≈ | 330.5 k | 604.5 k | 1.5 m ≈ |
| Capex | 30.6 k ≈ | 315.2 k | 3.6 k | 17.6 k ≈ | 15.2 k ≈ | 22.5 k | 9.9 k | 19.1 k ≈ |
| Dividends paid | 1.6 m ≈ | 0 | 1.6 m | 10.3 k ≈ | 1.1 m ≈ | 0 | 1.1 m | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 60 percentile of its own 5-quarter history (min 12.9, median 13.5, max 18.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.4 m | 13.6 k | 11.0 m | 13.9 m | 12.7 m | 10.9 m | 12.2 m | 10.5 m |
| Revenue YoY | +3.7% | −99.9% | +80,685.4% | +26.8% | −8.8% | −14.3% | +11.9% | −13.4% |
| Net income | 4.4 m | 4.8 m | 3.3 m | 4.7 m | 2.6 m | 2.6 m | 3.3 m | 2.1 m |
| Net income YoY | +13.2% | +9.4% | −30.6% | +41.0% | −44.8% | +0.5% | +25.9% | −35.2% |
| Diluted EPS | unavailable | unavailable | unavailable | 1.01 | 0.56 | 0.56 | 0.71 | 0.46 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | −44.6% | 0.0% | +26.8% | −35.2% |
| net % | 32.4% | 35,014.9% | 30.1% | 33.4% | 20.2% | 23.7% | 26.7% | 20.0% |
| Free cash flow | 4.9 m | 4.4 m | 3.6 m | 5.2 m | 2.4 m | 3.0 m | 3.0 m | 1.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 11.2 m USD
- Total assets
- 13.1 m USD
- Debt / equity
- unavailable
- Current ratio
- 7.31x
- ROE
- 18.2%
- ROA
- 15.7%
- FCF margin
- 18.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 11.0 m | 13.9 m | 12.7 m | 10.9 m | 12.2 m | 10.5 m | SEC (XBRL)· 27 Mar 2026verified |
| Cost of revenue | 4.9 m | 5.7 m | 6.0 m | 5.5 m | 5.7 m | 5.4 m | SEC (XBRL)· 27 Mar 2026verified |
| Gross profit | 6.1 m ≈ | 8.2 m ≈ | 6.7 m ≈ | 5.4 m ≈ | 6.5 m ≈ | 5.1 m ≈ | SEC (XBRL)· 27 Mar 2026derived |
| Research & development | 451.2 k | 478.6 k | 490.8 k | 464.0 k | 456.8 k | 463.6 k | SEC (XBRL)· 27 Mar 2026verified |
| Operating income | 3.6 m | 5.7 m | 4.0 m | 2.9 m | 3.6 m | 2.2 m | SEC (XBRL)· 27 Mar 2026verified |
| Depreciation & amortisation | 165.3 k | 146.0 k | 135.4 k | 105.7 k | 95.9 k | 108.2 k | SEC (XBRL)· 27 Mar 2026verified |
| EBITDA | 3.8 m ≈ | 5.8 m ≈ | 4.2 m ≈ | 3.0 m ≈ | 3.7 m ≈ | 2.4 m ≈ | SEC (XBRL)· 27 Mar 2026derived |
| Pre-tax income | 4.2 m | 5.9 m | 3.2 m | 3.3 m | 4.1 m | 2.6 m | SEC (XBRL)· 27 Mar 2026verified |
| Income tax | 856.0 k | 1.2 m | 658.2 k | 669.4 k | 857.6 k | 537.3 k | SEC (XBRL)· 27 Mar 2026verified |
| Net income | 3.3 m | 4.7 m | 2.6 m | 2.6 m | 3.3 m | 2.1 m | SEC (XBRL)· 27 Mar 2026verified |
| Diluted EPS | — | 1.01 | 0.56 | 0.56 | 0.71 | 0.46 | SEC (XBRL)· 27 Mar 2026verified |
| Dividend per share | — | — | — | 0.10 | 0.60 | — | SEC (XBRL)· 21 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 591.4 k | 531.2 k | 830.5 k | 8.2 m | 1.9 m | 1.3 m | SEC (XBRL)· 27 Mar 2026verified |
| Receivables | 1.4 m | 1.8 m | 1.4 m | 1.6 m | 1.4 m | 1.6 m | SEC (XBRL)· 27 Mar 2026verified |
| Inventories | 1.4 m | 1.4 m | 1.7 m | 1.2 m | 1.5 m | 1.5 m | SEC (XBRL)· 27 Mar 2026verified |
| Current assets | 11.2 m | 11.6 m | 10.0 m | 12.3 m | 12.7 m | 12.2 m | SEC (XBRL)· 27 Mar 2026verified |
| Property, plant & equipment, net | 673.7 k | 658.9 k | 559.2 k | 619.2 k | 956.4 k | 907.2 k | SEC (XBRL)· 27 Mar 2026verified |
| Total assets | 11.9 m | 12.2 m | 10.6 m | 12.9 m | 13.8 m | 13.1 m | SEC (XBRL)· 27 Mar 2026verified |
| Accounts payable | 31.8 k | 410.9 k | 30.4 k | 134.4 k | 425.0 k | 480.8 k | SEC (XBRL)· 27 Mar 2026verified |
| Current liabilities | 1.4 m | 2.3 m | 1.4 m | 1.5 m | 1.9 m | 1.7 m | SEC (XBRL)· 27 Mar 2026verified |
| Total liabilities | — | — | — | 1.5 m | 1.9 m | 1.9 m | SEC (XBRL)· 27 Mar 2026verified |
| Equity | 10.4 m † | 9.8 m † | 9.3 m † | 11.4 m † | 11.9 m † | 11.2 m † | SEC (XBRL)· 27 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.6 m | 5.3 m | 2.5 m | 3.1 m | 3.5 m | 2.0 m | SEC (XBRL)· 27 Mar 2026verified |
| Capex | 43.4 k | 116.4 k | 75.2 k | 165.7 k | 433.1 k | 59.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Free cash flow | 3.6 m ≈ | 5.2 m ≈ | 2.4 m ≈ | 3.0 m ≈ | 3.0 m ≈ | 1.9 m ≈ | SEC (XBRL)· 27 Mar 2026derived |
| Investing cash flow | -468.7 k | -183.5 k | 897.6 k | 4.7 m | -7.1 m | 175.3 k | SEC (XBRL)· 27 Mar 2026verified |
| Financing cash flow | -3.6 m | -5.2 m | -3.1 m | -459.4 k | -2.8 m | -2.8 m | SEC (XBRL)· 27 Mar 2026verified |
| Dividends paid | 3.6 m | 5.2 m | 3.1 m | 459.4 k | 2.8 m | 2.8 m | SEC (XBRL)· 27 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 69 / 100
A scoring methodology on indicators and valuation, not investment advice.
score >= 65 · margin_of_safety >= 0.15 · agreement in ['high', 'medium']
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 31.5 m USD
Key indicators
Coverage and freshness
Score by group
- Balance sheet100
- Growth0
- Quality100
- Returns90
- Valuation92
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 7.88 – 11.94 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E8.32 – 11.94 (Mid 10.35)4 companies used · median multiple 19.3x · quartiles 15.5x – 22.2xAXIL, IPAR, KVUE, ODD
- Dividend discount (DDM)7.88 – 10.60 (Mid 9.04)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Attractive profile · Score 69/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 22.0% | 100 (vs peers) | 10% |
| FCF conversion · Quality | 137.9% | 100 (on a fixed band) | 10% |
| Revenue CAGR 3Y · Growth | -6.0% | 0 (on a fixed band) | 13% |
| EPS CAGR 3Y · Growth | -6.3% | 0 (on a fixed band) | 13% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 7.3x | 100 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 12.8x | 86 (vs peers) | 17% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 10.8% | 100 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | 7.3% | 100 (on a fixed band) | 10% |
| Payout ratio (FCF) · Returns | 67.6% | 75 (on a fixed band) | 7% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality100/100 · 2/3 factors with a value
- Returns90/100 · 2/2 factors with a value
- Valuation92/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
UNITED-GUARDIAN, INC. (UG). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 10.5 m USD in 2025; YoY growth -13.4%; net margin 22.0%; ROE 21.4%.
The estimated value range is 8.10–11.27 USD per share (median of 2 methods, agreement: high); assumptions are illustrative. Against the central value of 9.70 USD, the price of 6.86 USD leaves a potential of 41.4% (value / price − 1) and a margin of safety of 29.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 69/100, methodological classification: attractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: balance. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 22.0%
- FCF conversion: 137.9%
- Current ratio: 7.3x
- P/E (TTM): 12.8x
- FCF yield: 10.8%
- Shareholder yield (distributions): 7.3%
- Payout ratio (FCF): 67.6%
- The price is below the estimated value range
What contradicts it
- Revenue CAGR 3Y: -6.0%
- EPS CAGR 3Y: -6.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net debt / EBITDA, Interest coverage, EV/EBITDA.
Versus the vertical median
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CLColgate-Palmolive Company | 78.5 bn | 38.7 | 358.9% | 9.6% | +1.4% | +23% / +25% |
| KVUEKenvue Inc. | 37.1 bn | 21.9 | 16.3% | 10.9% | −2.1% | +34% / +4% |
| ELFe.l.f. Beauty, Inc. | 6.7 bn | 113.6 | 6.0% | 3.4% | +24.6% | +49% / −4% |
| IPARInterparfums, Inc. | 4.0 bn | 23.3 | 19.5% | 11.3% | +2.5% | +52% / −1% |
| COTYCoty Inc. | 3.1 bn | — | -18.5% | -10.4% | −1.5% | +5% / −70% |
| EPCEdgewell Personal Care Company | 1.4 bn | — | -6.2% | -4.2% | −1.3% | +66% / −15% |
| SLSNSolesence, Inc. | 64.6 m | — | -15.1% | -3.8% | +18.6% | −60% / +22% |
| AXILAxil Brands, Inc. | 38.2 m | 16.7 | 23.3% | 9.3% | +17.5% | +10% / unavailable |
| UGUnited-Guardian, Inc. | 31.5 m | 12.8 | 21.4% | 22.0% | −13.4% | −3% / +18% |
| CABRCaring Brands, Inc. | 9.3 m | — | -3,889.1% | -183,298.7% | unavailable | −13% / unavailable |
| BNKKBonk, Inc. | 9.3 m | — | -332.4% | -2,330.4% | +201.6% | −82% / −99% |
| YCBDcbdMD, Inc. | 4.5 m | — | -40.3% | -13.8% | −1.5% | −34% / −93% |
| ELEstee Lauder Companies Inc | — | 111.7 | 9.3% | 2.4% | +5.0% | +19% / −12% |
| YSGYatsen Holding Limited | — | — | -2.7% | -1.9% | +32.2% | −67% / −49% |
| ODDOddity Tech Ltd | — | 12.0 | 32.6% | 13.7% | +25.2% | −50% / −37% |
| HLNHaleon plc | — | — | 10.2% | 15.1% | −1.8% | −6% / +8% |
1- and 3-year price returns: for UG from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 3.67 Total return -41% · Per year -41% | 6.52 Total return 2% · Per year 2% | 9.86 Total return 53% · Per year 53% |
| 3 years | 2.91 Total return -43% · Per year -17% | 5.88 Total return 7% · Per year 2% | 9.86 Total return 71% · Per year 20% |
| 5 years | 2.31 Total return -44% · Per year -11% | 5.31 Total return 11% · Per year 2% | 9.86 Total return 89% · Per year 14% |
- Exit P/E± 1.47
- Net margin± 1.03
- Annual revenue growth± 0.93
- Annual dilution± 0.09
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
United-Guardian makes cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness ingredients through its Guardian Laboratories division. Net sales rose 12% in the first half of 2026 3, a recovery after the largest cosmetic distributor had worked off excess stock, though pharmaceutical pricing and trade policy remain sensitive points.
SWOT
Strengths
Weaknesses
- Sales are concentrated among a few distributors and customers, so losing one partner would have a large effect on results 12.
- Sexual wellness sales were nearly absent in 2025, so the new line has no commercial track record yet 1.
- Production is concentrated in a single facility, which increases operational dependence on one site 1.
Opportunities
Risks
- Dependence on distributorshigh
A single distributor carries a large share of cosmetic sales, and renegotiation of the ASI agreement could affect volumes 12.
- Customer concentrationhigh
Receivables are concentrated in a small number of customers, so a change in the financial position of one of them would have a significant impact 1.
- Tariff policymedium
Tariffs and trade measures by several countries could affect volumes, prices and costs 1.
- Pharmaceutical regulationmedium
Changes to Medicare rebate programs could increase the company's obligations, particularly in later years 1.
- Order volatilitylow
Large orders from customers in India and from distributors can swing sharply, which has already reduced medical lubricant sales 2.
Investment thesis
What would need to be true (bull case)
- If the recovery in distributor orders and Renacidin growth persist, half-year sales could keep rising, as recent results show 23.
- The Natrajel launch and new distribution agreements could open new markets, particularly in France and North America 1.
- Net income rose faster than sales in the first half of 2026, which suggests good cost discipline 3.
What would break the thesis
What to watch
- Renacidin sales trend after formulary inclusionQ3 2026
- Outcome of the renegotiation of the ASI agreement2026
- First Natrajel sales figures through BrenntagQ4 2026
- Recovery of orders from the largest medical lubricant customernext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
United-Guardian, Inc. is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants 1. Its R&D focuses on new natural ingredients, and all products except Renacidin are made in Hauppauge, New York 1. The company operates as a single business segment with four product categories 1.
The company relies on distribution partners: Ashland Specialty Ingredients is the largest cosmetic ingredient distributor, and in January 2026 a new agreement with Brenntag Specialties was signed for the Natrajel line, which had no sales in 2025 1. Customers are mainly manufacturers of cosmetic products and medical devices 1.
Segments
Market context
Cosmetic ingredients are sold into markets described as stable and growing, such as personal care, medical devices and healthcare 1. The company says price pressure from low-cost competitors is significant, but its hydrogel innovation sets it apart 1.
The company describes the sexual wellness market as growing faster than other cosmetic segments, although Natrajel sales were only nominal in the second quarter of 2026 2. This could become meaningful if distribution through the new partners expands.
Trends
- Trade policy and tariffsheadwind
Changes in U.S. trade policy and higher tariffs could affect the company's volumes, prices and costs, especially for materials and supply chains 1.
- Demand for natural productstailwind
Consumer demand for green and natural products supports the launch of COSMOS-certified lines and preservative-free versions 1.
- Formulary access for medicinesmixed
Inclusion of Renacidin on PBM formularies could improve patient access, but rebate pressure and Medicare rules could reduce margins 12.
- Recovery of distributor ordersmixed
If ASI keeps resuming normal purchases, cosmetic sales could stay firm, but past overstock shows that volumes can be volatile 2.
Competitive position
The company faces low-cost competitors in the cosmetic hydrogel market, which has pressured prices 1. Its stated advantages are innovation, product quality and its supply chain 1.
In sexual wellness and medical lubricants, competition comes from suppliers of similar materials and products, and losing a major customer can quickly affect results 2.
- Ashland Specialty Ingredients
The company's largest cosmetic distributor, whose order levels can strongly influence volumes.
- Brenntag Specialties
New distributor for the Natrajel line in the United States, Canada, Mexico and France.
- Azelis Group
Distributor for cosmetic ingredients in South Korea, the United Kingdom and Ireland, and for medical lubricants.
- Sederma SAS
Cosmetic ingredient distributor in France, a subsidiary of a British chemicals group.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report11 Aug 2026
- Current report07 Aug 2026Results of operations · Financial statements and exhibits
- Current report16 Jul 2026Regulation FD disclosure · Financial statements and exhibits
- Current report15 May 2026Shareholder vote
- Quarterly report12 May 2026
- Current report08 May 2026Results of operations · Financial statements and exhibits
- Proxy statement06 Apr 2026
- Annual report27 Mar 2026
- Current report27 Mar 2026Results of operations · Financial statements and exhibits
- Current report29 Jan 2026Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / United-Guardian, Inc. · 27 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / United-Guardian, Inc. · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / United-Guardian, Inc. · 07 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.